The 2026 Pharmaceutical Reckoning: Inside the Surge of Depo-Provera Meningioma Litigation
The landscape of pharmaceutical accountability has reached a critical juncture in early 2026. Following the U.S. Food and Drug Administration’s (FDA) December 2025 decision to mandate a brain tumor warning label for medroxyprogesterone acetate—marketed widely as Depo-Provera—thousands of women have stepped forward. What began as a series of isolated claims has evolved into a massive legal movement,…
